Urinary Vitamin C Loss in Diabetic Subjects
Urinary Vitamin C Loss in Diabetic Subjects
Several studies have reported that diabetic subjects have lower plasma vitamin C
 concentrations than non-diabetic subjects. Although urinary vitamin C loss in diabetic
 subjects was reported to be increased in two studies, these are difficult to interpret due to
 lack of controlled vitamin C intake, inadequate sampling, lack of control subjects, or
 methodology uncertainties in vitamin C assay and sample processing. Consequently, it is
 unclear whether diabetic subjects truly have both low plasma and high urine vitamin C
 concentrations. We propose that low plasma vitamin C concentrations in diabetic subjects are
 due in part to inappropriate renal loss of vitamin C in these subjects but not in healthy
 controls. We will study vitamin C concentrations in patients with type 1 and type 2 diabetes
 and in matched healthy research subjects. Vitamin C concentrations in plasma, neutrophils (as
 a proxy for tissue concentrations) and in urine will be measured in outpatients. In those
 willing to be admitted to the Clinical Center, we will measure 24-hour urinary excretion of
 vitamin C while on a vitamin C free diet, and creatinine clearance, a measure of glomerular
 filtration rate. On day 2 of the inpatient study, subjects will receive a single 200mg dose
 of oral vitamin C and we will measure vitamin C concentrations in frequent blood and urine
 samples to determine the renal threshold and relative bioavailability for vitamin C. Single
 nucleotide polymorphisms (SNPs) will be determined in genomic DNA responsible for the two
 proteins mediating sodium-dependent vitamin C transport, SVCT1 and SVCT2. If low plasma and
 high urine vitamin C concentrations are found in diabetic subjects, further studies will be
 needed to explore mechanisms and to determine recommended dietary allowances for this patient
 population.
Several studies have reported that diabetic subjects have lower plasma vitamin C
 concentrations than non-diabetic subjects. Although urinary vitamin C loss in diabetic
 subjects was reported to be increased in two studies, these are difficult to interpret due to
 lack of controlled vitamin C intake, inadequate sampling, lack of control subjects, or
 methodology uncertainties in vitamin C assay and sample processing. Consequently, it is
 unclear whether diabetic subjects truly have both low plasma and high urine vitamin C
 concentrations. We propose that low plasma vitamin C concentrations in diabetic subjects are
 due in part to inappropriate renal loss of vitamin C in these subjects but not in healthy
 controls. We will study vitamin C concentrations in patients with type 1 and type 2 diabetes
 and in matched healthy research subjects. Vitamin C concentrations in plasma, neutrophils (as
 a proxy for tissue concentrations) and in urine will be measured in outpatients. In those
 willing to be admitted to the Clinical Center, we will measure 24-hour urinary excretion of
 vitamin C while on a vitamin C free diet, and creatinine clearance, a measure of glomerular
 filtration rate. On day 2 of the inpatient study, subjects will receive a single 200mg dose
 of oral vitamin C and we will measure vitamin C concentrations in frequent blood and urine
 samples to determine the renal threshold and relative bioavailability for vitamin C. Single
 nucleotide polymorphisms (SNPs) will be determined in genomic DNA responsible for the two
 proteins mediating sodium-dependent vitamin C transport, SVCT1 and SVCT2. If low plasma and
 high urine vitamin C concentrations are found in diabetic subjects, further studies will be
 needed to explore mechanisms and to determine recommended dietary allowances for this patient
 population.
-  INCLUSION CRITERIA:

 We propose to study an unlimited number of male and female subjects between the ages of 18
 and 65. This will include healthy subjects and subjects with type 1 or type 2 diabetes. To
 be included in the study, study subjects should

 -  be in good general health

 -  have no significant illnesses that compromise clinical stability other than the
 complications of diabetes mellitus alone or in the context of metabolic syndrome.
 Subjects with ischemic heart disease and/or peripheral artery disease are eligible for
 arm 1 of the protocol.

 -  have serum creatinine < 2.5

 -  for healthy volunteers, be normotensive at the time of the study, with a blood
 pressure less than or equal to 140/90

 -  for diabetic subjects, blood pressure less than or equal to 170/95 as long as
 clinically stable and in usual state of health, for example, no chest pain, shortness
 of breath, headache, syncope or fatigue

 The aim of this study is to determine whether diabetic subjects lose vitamin C in the urine
 in their normal clinical condition (i.e. while on treatment) and not in the native
 untreated state of uncontrolled hyperglycemia. Therefore the patients will not discontinue
 medication.

 EXCLUSION CRITERIA (for arm 1):

 Exclusion criteria will include the following:

 -  significant organ malfunction leading to clinical instability including liver disease,
 pulmonary disease, stroke and anemia at investigator discretion

 -  serious or chronic illness or history of serious or chronic illness resulting in
 clinical instability other than complications of diabetes

 -  pregnancy

 -  alcohol abuse, drug addiction or the use of illegal drugs

 -  positive HIV or hepatitis (B or C) screening tests (subjects will be notified of these
 test results).

 -  presence of other concomitant conditions which in the judgment of the investigators
 can influence vitamin C metabolism or vitamin C renal handling

 EXCLUSION CRITERIA (for arms 2 and 3):

 Exclusion criteria will include the following:

 -  significant organ malfunction leading to clinical instability including liver disease,
 pulmonary disease, ischemic heart disease, heart failure, stroke, peripheral vascular
 disease, and anemia at investigator discretion

 -  other serious or chronic illness; history of serious or chronic illness; coronary
 artery disease, or peripheral vascular disease resulting in clinical instability

 -  pregnancy

 -  alcohol abuse, drug addiction or the use of illegal drugs

 -  positive HIV or hepatitis (B or C) screening tests (subjects will be notified of these
 test results).

 -  presence of other concomitant conditions which in the judgment of the investigators
 can influence vitamin C metabolism or vitamin C renal handling

 For inpatient subjects, an additional exclusion criterion is consumption during the
 hospitalization of any foods or beverages other than those in the vitamin C free diet.